• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    5/22/24 8:06:41 AM ET
    $AHG
    $CING
    $COEP
    $DMTK
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • Mustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 30.78% to $5.99. The market value of their outstanding shares is at $29.3 million.
    • Rezolute (NASDAQ:RZLT) shares rose 25.0% to $3.75. The company's market cap stands at $150.5 million.
    • Akso Health Group (NASDAQ:AHG) stock moved upwards by 16.26% to $1.0. The market value of their outstanding shares is at $146.6 million.
    • Coeptis Therapeutics (NASDAQ:COEP) shares increased by 15.72% to $0.39. The company's market cap stands at $14.4 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) stock rose 13.33% to $0.82. The company's market cap stands at $29.1 million.

    Losers

    • LifeStance Health Gr (NASDAQ:LFST) stock declined by 18.6% to $6.09 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.3 billion.
    • Lipella Pharmaceuticals (NASDAQ:LIPO) stock fell 11.84% to $0.64. The company's market cap stands at $4.8 million.
    • DermTech (NASDAQ:DMTK) shares fell 10.43% to $0.32. The company's market cap stands at $11.1 million.
    • Cingulate (NASDAQ:CING) shares decreased by 9.97% to $0.75. The market value of their outstanding shares is at $4.5 million.
    • Tharimmune (NASDAQ:THAR) shares declined by 9.35% to $0.35. The company's market cap stands at $4.1 million.
    • Longeveron (NASDAQ:LGVN) stock decreased by 9.22% to $1.08. The market value of their outstanding shares is at $6.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $CING
    $COEP
    $DMTK

    CompanyDatePrice TargetRatingAnalyst
    Rezolute Inc.
    $RZLT
    3/25/2026$5.00Neutral → Outperform
    Wedbush
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    LifeStance Health Group Inc.
    $LFST
    12/9/2025$8.00Overweight
    Barclays
    LifeStance Health Group Inc.
    $LFST
    11/13/2025$8.00Outperform
    BMO Capital Markets
    LifeStance Health Group Inc.
    $LFST
    7/25/2025$8.00Buy
    BTIG Research
    LifeStance Health Group Inc.
    $LFST
    5/27/2025$8.50Neutral → Buy
    UBS
    More analyst ratings

    $AHG
    $CING
    $COEP
    $DMTK
    SEC Filings

    View All

    SEC Form 424B3 filed by Cingulate Inc.

    424B3 - Cingulate Inc. (0001862150) (Filer)

    3/27/26 4:01:35 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Cingulate Inc.

    EFFECT - Cingulate Inc. (0001862150) (Filer)

    3/27/26 12:15:29 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Coeptis Therapeutics Holdings Inc.

    SCHEDULE 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    3/26/26 11:22:27 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $CING
    $COEP
    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

    REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.    In December 2025, the Company reported that sunRIZE demonstrated reductions from baseline in hypoglycemia events, but the study did not meet its primary endpoint because 

    3/24/26 7:00:00 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, "Cingulate delivered on key inflection points throughout 2025 and this continues i

    3/18/26 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $CING
    $COEP
    $DMTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP and CFO Callahan Jennifer L. bought $24,515 worth of shares (4,864 units at $5.04), increasing direct ownership by 2,494% to 5,059 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Schaffer Shane J. bought $34,317 worth of shares (6,809 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:19 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Werth Peter J. bought $98,053 worth of shares (19,455 units at $5.04) (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    2/10/26 7:00:20 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $CING
    $COEP
    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute upgraded by Wedbush with a new price target

    Wedbush upgraded Rezolute from Neutral to Outperform and set a new price target of $5.00

    3/25/26 8:24:55 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $CING
    $COEP
    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Liu Wenjuan

    3 - Akso Health Group (0001702318) (Issuer)

    3/27/26 6:46:26 AM ET
    $AHG
    Real Estate

    SEC Form 4 filed by Mcgroarty Ryan

    4 - LifeStance Health Group, Inc. (0001845257) (Issuer)

    3/26/26 9:22:32 AM ET
    $LFST
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Mcgroarty Ryan

    4 - LifeStance Health Group, Inc. (0001845257) (Issuer)

    3/19/26 4:52:36 PM ET
    $LFST
    Medical/Nursing Services
    Health Care

    $AHG
    $CING
    $COEP
    $DMTK
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $CING
    $COEP
    $DMTK
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026

    SCOTTSDALE, Ariz., Feb. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its fourth quarter and full year 2025 earnings release before the market opens on Wednesday, February 25, 2026. LifeStance will host a live earnings conference call to discuss fourth quarter and full year results on February 25, 2026, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 3993891, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentat

    2/9/26 4:10:00 PM ET
    $LFST
    Medical/Nursing Services
    Health Care

    $AHG
    $CING
    $COEP
    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:09:22 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care